Clinical trials: Cirrhosis Liver
Spontaneous Bacterial Peritonitis
Prediction of SBP in Cirrhotic Patients by Platlet Count, Na and AlBl Index.
This study aims to evaluate whether integrating serum sodium levels and platelet count with the Albumin-Bilirubin (ALBI) score can improve the early prediction of spontaneous bacterial peritonitis (SBP) in cirrhotic patients with…
- Trial name
- NCT07116369
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Viral Hepatitis, Liver Fibrosis
Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
This study is being conducted to develop new techniques for early diagnosis of liver disease. These techniques are: Shearwave Elastography (SWE) ultrasound and blood biomarkers.
- Conditions
- Viral Hepatitis, Liver Fibrosis, Liver Disease, Hepatitis B
- Trial name
- NCT01988753
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Baylor College of Medicine
Septic Shock, Vasoplegia
Evaluating in Cirrhotics With Refractory Vasoplegia the Effect of Methylene Blue
Mortality rates associated septic shock remains unacceptably high, around 20-50%, with refractory hypotension in half of these patients.
- Conditions
- Septic Shock, Vasoplegia, Cirrhosis, Liver, Refractory Shock
- Trial name
- CRuMBS (NCT03120637)
- Testing
- Methylene Blue
- Where
- India
- Volunteers
- 111 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cirrhosis, Liver, Portal Hypertension
Timing of Endoscopy for Acute Variceal Bleeding in Patients With Cirrhosis
Cirrhotic patients with AVB across 34 university medical centers in 30 cities in China from February 2013 to May 2020 who underwent endoscopy within 24 hours were included in this study.
- Conditions
- Cirrhosis, Liver, Portal Hypertension, Varice Bleed
- Trial name
- NCT04957875
- Testing
- emergency endoscopic therapy
- Where
- China
- Volunteers
- 3,300 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Hepatitis C, Cirrhosis
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
This study will evaluate the antiviral efficacy of combination therapy with sofosbuvir (SOF) plus ribavirin (RBV) for 48 weeks in adults with compensated and decompensated chronic hepatitis C virus (HCV) infection.
- Conditions
- Hepatitis C, Cirrhosis, Portal Hypertension, With or Without Liver Decompensation
- Trial name
- NCT01687257
- Testing
- SOF, RBV
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 50 people
- Sponsor
- Gilead Sciences
End Stage Liver DIsease, Liver Transplant; Complications
Intraoperative Normal Saline Administration and Acute Kidney Injury in Patients Undergoing Liver Transplantation
The investigators attempted to investigate the association of the type of crystalloid administered during liver transplantation with postoperative clinical outcomes.
- Conditions
- End Stage Liver DIsease, Liver Transplant; Complications, Liver Cirrhosis
- Trial name
- NCT05386953
- Testing
- Normal saline, Balanced crystalloid solution
- Where
- South Korea
- Volunteers
- 1,440 people
- Sponsor
- Seoul National University Hospital
Cirrhosis, Spontaneous Bacterial Peritonitis
Early Ascitis Parencentesis in SBP
Paracentesis at 48 hours, as recommended in international guidelines, could delay the time to effective antibiotic therapy in cases of SBP with germs resistant to empirical antibiotic therapy.
- Trial name
- PAPISLA (NCT06679842)
- Testing
- ascitis paracentesis
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Septic Shock, Cirrhosis, Liver
Efficacy and Safety of Vasopressin Versus Terlipressin as a Second Vasopressor in Critically Ill Cirrhotics With Septic Shock- the VITEL-C Trial
Sepsis is a life-threatening organ dysfunction caused by dysregulated host response. A Subset of sepsis is septic shock which has almost 4-6 times the mortality when compared to sepsis.
- Trial name
- NCT05315557
- Testing
- Terlipressin, vasopressin
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cirrhosis, Liver
Rotational Thromboelastometry Guided Blood Component Use in Children With Cirrhosis Undergoing Invasive Procedures: A Randomized Controlled Trial
Blood products are commonly used before invasive procedures in patients with end-stage liver diseases despite cirrhosis being a thrombophilic state.
- Trial name
- NCT04460222
- Testing
- Rotational Thromboelastometry to guide blood product transfusion pre invasive procedure, Conventional transfusion methods to guide blood product transfusion pre invasive procedure
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cirrhosis, Splenectomy
Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS
The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy.
- Conditions
- Cirrhosis, Splenectomy, Portal Vein Thrombosis, Hypertension, Portal
- Trial name
- NCT07461545
- Testing
- Apixaban 2.5 MG
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Northern Jiangsu People's Hospital
Liver Cirrhosis
Transient Elastography in Autoimmune Hepatitis
Recent, research has focused on the evaluation of non-invasive methods for the assessment of liver fibrosis in patients with chronic liver disease. Among these methods, transient elastography is the most promising.
- Trial name
- NCT01905254
- Testing
- Transient elastography (TE), Liver biopsy
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Primary Biliary Cirrhosis
Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis
The University of Michigan is conducting a study investigating a potential new treatment aimed at slowing/halting progression of primary biliary cirrhosis.
- Trial name
- NCT00805805
- Testing
- Tetrathiomolybdate
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- George Brewer
Glucose Metabolism Disorders, Liver Fibrosis
Change of Glucose Metabolism and Fibrosis Markers in Patients With Hepatitis C Under Treatment With Antiviral Agents
Chronic hepatitis C infection is associated with changes of glucose metabolism end increased frequency of impaired glucose tolerance. This might be a additional risk factor for disease and fibrosis progression.
- Conditions
- Glucose Metabolism Disorders, Liver Fibrosis, Hepatitis C
- Trial name
- NCT03908294
- Testing
- Lab tests, non-invasive fibrosis (Fibroscan/ARFI)
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Hepatocellular Carcinoma
The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs
This cohort study aims to evaluate the validation of general evaluation score in the prediction of hepatocellular carcinoma risk among patients with advanced fibrosis (F3) and cirrhosis (F4) who achieved sustained virological…
- Trial name
- NCT06325826
- Testing
- General Evaluation Score (GES)
- Where
- Egypt
- Volunteers
- 500 people
- Sponsor
- Egyptian Liver Hospital
Liver Cirrhosis
Supplemental Corticosteroids in Cirrhotic Hypotensive Patients With Suspicion of Sepsis
The main goal of the study is to investigate the clinical relevance, efficacy and safety of treating hypotensive cirrhotic patients with suspicion of sepsis and on vasopressors with low-dose hydrocortisone in order to reverse…
- Trial name
- SCOTCH; (NCT02602210)
- Testing
- Hydrocortisone, NaCL 0.9%
- Where
- 10 sites in Belgium, Czechia and 5 more
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Obesity, Morbid, Liver Fibrosis
Performances Evaluation of New FibroScan Probes Dedicated to Morbidly Obese Patients
Non-Alcoholic Fatty Liver is a common clinical and histological condition associated with metabolic syndrome in patients with and without excess body weight.
- Trial name
- NCT03872024
- Testing
- For the first 60 patients: 3 XXL probe prototypes of the FibroScan 630 Research Model, From patient 61 to patient 120: 1 XXL probe prototype of the FibroScan 630 Research Model
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Echosens
Cirrhosis, Kidney Injury
Impact of Acute Kidney Injury on Sarcopenia and Frailty in Patients With Liver Cirrhosis
The aim of this prospective observational study is to evaluate the impact of acute kidney injury on sarcopenia and frailty in patients with liver cirrhosis.
- Conditions
- Cirrhosis, Kidney Injury, Sarcopenia, Frailty
- Trial name
- NCT05389280
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Kangbuk Samsung Hospital
Decompensated Cirrhosis Ethanol Related
Effect of Whey Protein Versus Egg Albumen Protein Challenge on Blood Ammonia Level in Patients of Decompensated Ethanol Related Cirrhosis.
In cirrhosis, altered nitrogen metabolism and reduced hepatic clearance of ammonia contribute to the development of Minimal Hepatic Encephalopathy (MHE)-a subclinical but functionally debilitating condition.
- Trial name
- NCT07299110
- Testing
- Whey Protein, Egg Albumen
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypothyroidism
Hypothyroidism and Liver Fibrosis Severity in MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, characterized by excess fat accumulation in the liver associated with metabolic risk factors such as obesity and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypothyroidism, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT07793279
- Volunteers
- 85 people
- Sponsor
- Assiut University
Cirrhosis
Spleen Stiffness Measurement With FibroScan
FibroScan® (Echosens, Paris, France) is an active non implantable medical device marketed in Europe since December 2003 and is currently used in many countries.
- Trial name
- NCT02180113
- Testing
- Fibroscan® examination
- Where
- 7 sites in France, Italy and 2 more
- Volunteers
- 403 people, healthy volunteers welcome
- Sponsor
- Echosens